Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Attgeno AB currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This volume of activity suggests a targeted approach to their intellectual property, likely focusing on a specific biological discovery. The concentration of efforts in the Biotechnology & Pharmaceuticals sector indicates that the company's current legal strategy is centered on this technical domain.
The prosecution is managed by 1 distinct examiner and 1 distinct art unit, ensuring a highly focused examination environment. This alignment between 1 distinct examiner and 1 distinct art unit allows for a consistent dialogue between the applicant and the USPTO, as there are no conflicting viewpoints from other examiners. The presence of 1 distinct art unit suggests that the technology is classified within a specific and well-defined technical niche.
SZNAIDMAN, MARCOS L is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending action. As the examiner assigned to the company's active matter, SZNAIDMAN, MARCOS L will determine the immediate success of the prosecution. Practitioners should review the examiner's history within the Biotechnology & Pharmaceuticals field to better anticipate potential rejections for the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927780 | MONO- AND BIS-NITROSYLATED ALKYL POLYOLS FOR THERAPEUTIC USE | SZNAIDMAN, MARCOS L | 51d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927780 | MONO- AND BIS-NITROSYLATED ALKYL POLYOLS FOR THERAPEUTIC USE | SZNAIDMAN, MARCOS L | 51d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17927780 | MONO- AND BIS-NITROSYLATED ALKYL POLYOLS FOR THERAPEUTIC USE | SZNAIDMAN, MARCOS L | 1628 | §103§112 | Final Rejection | 51d overdue | Pending | Nov 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial